For example, some tumors such as bile duct cancer (CHOL), head and neck cancer (HNSC), lung squamous cell carcinoma (LUSC), GBM, STAD, THCA, and BLCA exhibited high IGF2BP2 expression levels, while KIRC, breast cancer (BRCA), and UCEC were characterized by low levels of IGF2BP2 expression (Figure S1B). This evidence concerns the gene IGF2BP2 and squamous cell lung carcinoma.